PI + booster fixed-dose
Darunavir with cobicistat
Brand names: Rezolsta
Adult dose
Dose: 1 tablet (800/150mg) OD with food
Route: Oral
Frequency: OD
Clinical pearls
- BHIVA: option for combination ART; co-formulation simplifies dosing
- Drug-interaction review at every prescription
Contraindications
- As darunavir
- CrCl <70 if combined with TAF/TDF
- Hypersensitivity
Side effects
- As darunavir; cobicistat causes increased serum creatinine (artefactual)
Interactions
- As darunavir + cobicistat (potent CYP3A4 inhibitor)
Monitoring
- VL/CD4
- Creatinine
- LFTs
- Lipids
Reference: BNF; BHIVA HIV guidelines; EACS; https://bnf.nice.org.uk/drugs/darunavir-with-cobicistat/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023